MorphoSys’ Monjuvi (tafasitamab-cxix) + Lenalidomide Receives the US FDA’s Approval as 2L Treatment for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

 MorphoSys’ Monjuvi (tafasitamab-cxix) + Lenalidomide Receives the US FDA’s Approval as 2L Treatment for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

MorphoSys’ Monjuvi (tafasitamab-cxix) + Lenalidomide Receives the US FDA’s Approval as 2L Treatment for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Shots:

  • The approval is based on P-II L-MIND study assessing Monjuvi in combination with lenalidomide as a treatment for adult patients with relapsed or refractory DLBCL
  • Results: ORR (55%); CR (37%); PR (18%); mDOR (21.7mos.). Additionally, the US FDA has granted BT designation for the combination therapy for r/r DLBCL
  • Monjuvi is a humanized Fc-modified cytolytic CD19 targeting mAb, has been approved under US FDA’s accelerated approval, and is expected to be commercially available in the US. MorphoSys and Incyte will co-commercialize Monjuvi in the US & has exclusive commercialization rights outside the territory

Click here ­to­ read full press release/ article | Ref: MorphoSys | Image: StraitTimes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post